The Evaluation of 17 Gastrointestinal Tumor Markers Reveals Prognosis Value for MUC6, CK17, and CD10 in Gallbladder-Cancer Patients
| Autor: | Andrés Tittarelli, Paula Fluxá, C. Carrasco, Claudia Greppi Quezada, Maeva Del Pozo, Omar Barría, Daniel Rojas-Sepúlveda, Carolina Martin, Natalia Paillaleve, Melissa Hott, Flavio Salazar-Onfray |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Microarray Clinical Biochemistry Vimentin Disease Article gallbladder cancer 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Gallbladder cancer Pathological cytokeratin 17 lcsh:R5-920 Tissue microarray biology tissue microarray business.industry Gallbladder biomarkers mucin 6 medicine.disease 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis immunohistochemistry biology.protein Immunohistochemistry CD10 prognosis business lcsh:Medicine (General) |
| Zdroj: | Diagnostics Volume 11 Issue 2 Diagnostics, Vol 11, Iss 153, p 153 (2021) |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics11020153 |
| Popis: | Gallbladder cancer (GBC) is an aggressive and highly lethal disease with relatively low global incidence, but one that constitutes a major health problem in Asian and Latin American countries, particularly in Chile. The identification of new tumor-associated markers with potential prognosis value is required for GBC clinical practice. Using immunohistochemistry/tumor tissue microarray, we evaluated the expression of 17 gastrointestinal tumor-associated protein markers (CK7, CK17, CK19, CK20, CKLMW, CKHMW, MUC1, MUC2, MUC5AC, MUC6, CA125, CD10, CEA, vimentin, villin, claudin-4, and CDX2) in primary gallbladder adenocarcinomas from 180 Chilean patients and analyzed potential associations with their pathological and clinical characteristics. Younger female patients with well- to moderately differentiated tumors had a better prognosis than that of older female or male patients with tumors with a similar tumor differentiation grade. Among all analyzed markers, MUC6 expression was associated with better prognosis in patients with well- to moderately differentiated tumors, whereas CK17 or CD10 was associated with worse prognosis in patients with poorly differentiated tumors. In addition, the MUC6+CK17&ndash expression pattern was strongly associated with better prognosis in patients with well- to moderately differentiated tumors, whereas patients with poorly differentiated tumors and with the CK17+CD10+ expression pattern showed worse prognosis. Our results suggest that tumor MUC6, CK17, and CD10 can be considered as potential prognosis markers for GBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|